Resistance Management for Cancer: Lessons from Farmers.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
02 Oct 2024
Historique:
accepted: 23 09 2024
received: 28 10 2023
revised: 29 06 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: aheadofprint

Résumé

One of the main reasons we have not been able to cure cancers is that treatments select for drug-resistant cells. Pest managers face similar challenges with pesticides selecting for pesticide-resistant insects, resulting in similar mechanisms of resistance. Pest managers have developed ten principles that could be translated to controlling cancers: (1) prevent onset, (2) monitor continuously, (3) identify thresholds below which there will be no intervention, (4) change interventions in response to burden, (5) preferentially select non-chemical control methods, (6) use target-specific drugs, (7) use the lowest effective dose, (8) reduce cross-resistance, (9) evaluate success based on long-term management, and (10) forecast growth and response. These principles are general to all cancers and cancer drugs and so could be employed broadly to improve oncology. Here, we review the parallel difficulties in controlling drug resistance in pests and cancer cells. We show how the principles of resistance management in pests might be applied to cancer. Integrated pest management inspired the development of adaptive therapy in oncology to increase progression-free survival and quality of life in patients with cancers where cures are unlikely. These pest management principles have the potential to inform clinical trial design.

Identifiants

pubmed: 39356625
pii: 748776
doi: 10.1158/0008-5472.CAN-23-3374
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Sareh Seyedi (S)

Arizona State University, Tempe, Arizona, United States.

Valerie K Harris (VK)

Arizona State University, Tempe, United States.

Stefania E Kapsetaki (SE)

Tufts University, Medford, United States.

Shrinath Narayanan (S)

University of Lausanne, Lausanne, Vaud, Switzerland.

Daniel Saha (D)

Arizona State University, Tempe, Arizona, United States.

Zachary Compton (Z)

University of Arizona, Tucson, Arizona, United States.

Rezvan Yousefi (R)

Arizona State University, Tempe, Arizona, United States.

Alexander May (A)

Evolver Dynamics, Inc., Belleville, Ontario, Canada.

Efe Fakir (E)

Istanbul University Cerrahpasa School of Medicine,, Istanbul, Turkey, Turkey.

Amy M Boddy (AM)

University of California, Santa Barbara, United States.

Marco Gerlinger (M)

Queen Mary University of London, London, United Kingdom.

Christina Wu (C)

Mayo Clinic Hospital, Phoenix, Arizona, United States.

Lida Mina (L)

Mayo Clinic Hospital, Phoenix, AZ, United States.

Silvie Huijben (S)

Arizona State University, Tempe, United States.

Dawn H Gouge (DH)

University of Arizona, Tucson, Arizona, United States.

Luis Cisneros (L)

Arizona State University, Tempe, Arizona, United States.

Peter C Ellsworth (PC)

University of Arizona, Tucson, Arizona, United States.

Carlo C Maley (CC)

Arizona State University, Tempe, AZ, United States.

Classifications MeSH